Cargando…

Bone loss and the aromatase inhibitors

The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopau...

Descripción completa

Detalles Bibliográficos
Autores principales: Lester, J, Coleman, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361688/
https://www.ncbi.nlm.nih.gov/pubmed/16100521
http://dx.doi.org/10.1038/sj.bjc.6602691
_version_ 1782153275122909184
author Lester, J
Coleman, R
author_facet Lester, J
Coleman, R
author_sort Lester, J
collection PubMed
description The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future. Strategies for the identification and management of treatment-induced bone loss are currently being defined.
format Text
id pubmed-2361688
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616882009-09-10 Bone loss and the aromatase inhibitors Lester, J Coleman, R Br J Cancer Aromatase Inhibitors–Past, Present and Future The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future. Strategies for the identification and management of treatment-induced bone loss are currently being defined. Nature Publishing Group 2005-08 2005-08-15 /pmc/articles/PMC2361688/ /pubmed/16100521 http://dx.doi.org/10.1038/sj.bjc.6602691 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Aromatase Inhibitors–Past, Present and Future
Lester, J
Coleman, R
Bone loss and the aromatase inhibitors
title Bone loss and the aromatase inhibitors
title_full Bone loss and the aromatase inhibitors
title_fullStr Bone loss and the aromatase inhibitors
title_full_unstemmed Bone loss and the aromatase inhibitors
title_short Bone loss and the aromatase inhibitors
title_sort bone loss and the aromatase inhibitors
topic Aromatase Inhibitors–Past, Present and Future
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361688/
https://www.ncbi.nlm.nih.gov/pubmed/16100521
http://dx.doi.org/10.1038/sj.bjc.6602691
work_keys_str_mv AT lesterj bonelossandthearomataseinhibitors
AT colemanr bonelossandthearomataseinhibitors